PARTNERING STRATEGY

At Humanigen, Inc. we are committed to working with strategic and commercial partners, medical and academic institutions to maximize product and technology portfolio. We are dedicated to working in partnerships and collaborations to add value and fill unmet medical needs in life threatening conditions such as COVID-19, CAR-T, GvHD, CMML, Eosinophilic Diseases, GBM and other solid tumors. 

Humanigen Fact Sheets

Corporate
Cytokine Storm
Lenzilumab

Humanigen’s portfolio is broad and currently, we are open to strategic partnership discussions in the areas of:​​

Lenzilumab™ COVID-19 prevention / treatment of Hyper-inflammation / Cytokine Storm

Phase III & Launch

Lenzilumab CAR-T increased efficacy and safety

Phase I/II

Lenzilumab Eosinophilic Asthma

Phase III

Ifabotuzumab Solid tumors

Phase II

EMR1 Eosinophilic diseases

Phase I/II

Early stage opportunities for innovative programs with our proprietary CARs

AdobeStock_40694285.jpeg

Key areas we are looking for in Lenzilumab partners are:

Partners:

Multinational, Regional or Domestic Pharmaceutical or Biotechnology Company


Territories:

Global, Regional and Countries such as People’s Republic of China, Latin America, Russia, India and certain other Asia-Pacific countries are available for discussion


Product:

Lenzilumab (currently 10mg/ml filled into a 10ml vial)


Indications:

Treatment of hypoxic hospitalized COVID-19 pneumonia patients; treatment and prevention of CAR-T CRS and neurotoxicity and improvement in CAR-T efficacy


Clinical development:

Partner to complete required clinical development suitable for registration in the Territory


Regulatory:

Partner to submit for approval in the territory for the Indication.  Partner is free to reference EUA, BLA and any other approvals


Manufacturing:

Ideally partner will have experience in the manufacturing of mAbs and will complete the tech transfer of the process (to cGMP standard) from our current CMO’s.  If no manufacturing capability exist, partner may find a suitable CMO to supply Product. Alternatively, Partner may be able to purchase Product from Humanigen.


Commercialization:

Partner will need to have existing commercial infrastructure to commercialize and distribute lenzilumab to hospitals and other relevant institutions.

If you have an interest in Humanigen, or any of its portfolio or technologies to work together and achieve great outcomes for patients and their families, then please get in contact with:

Bob Atwill - Head of Asia-Pacific Region at: batwill@humanigen.com

PARTNERS AND COLLABORATION

Humanigen, Inc. currently has a number of Partners and Collaboration.

National Institute of Allergy and Infectious Diseases (“NIAID”)

COVID-19

Kite Pharmaceuticals, Inc.

CAR-T Therapies

IMPACT

GvHD

Humanigen, Inc. also has exclusive worldwide license agreements with the University of Zurich in GvHD and the Mayo Foundation for Medical Education and Research in CAR-T.

  • Twitter

©2020 Humanigen, Inc.  All rights reserved